These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 19201525)

  • 1. Editorial comment on: Vaccine therapy in patients with renal cell carcinoma.
    Bellmunt J; Ribas A
    Eur Urol; 2009 Jun; 55(6):1342-3. PubMed ID: 19201525
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial comment on: Vaccine therapy in patients with renal cell carcinoma.
    Clark PE
    Eur Urol; 2009 Jun; 55(6):1343-4. PubMed ID: 19201523
    [No Abstract]   [Full Text] [Related]  

  • 3. Vaccine therapy in patients with renal cell carcinoma.
    Van Poppel H; Joniau S; Van Gool SW
    Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active and passive immunotherapy: vaccines and antibodies.
    Oosterwijk E; Divgi C; Bander NH
    BJU Int; 2007 May; 99(5 Pt B):1301-4. PubMed ID: 17441928
    [No Abstract]   [Full Text] [Related]  

  • 5. High-dose interleukin-2 in metastatic renal cell carcinoma.
    Fernández-Rodríguez R; de Argumedo GL; Mañé JM; Muñoz A; Ferreiro J; Fuente N; López-Vivanco G
    J Clin Oncol; 2005 Sep; 23(27):6797-8; author reply 6798-9. PubMed ID: 16170190
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunotherapy and prognostic factors.
    Fumagalli LA; Brivio F
    J Clin Oncol; 2006 Sep; 24(25):4218-9; author reply 4219-20. PubMed ID: 16943541
    [No Abstract]   [Full Text] [Related]  

  • 7. New therapeutic developments in renal cell cancer.
    Prenen H; Gil T; Awada A
    Crit Rev Oncol Hematol; 2009 Jan; 69(1):56-63. PubMed ID: 18752971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is tumor response important for renal carcinoma?
    Inman BA; George DJ
    Eur Urol; 2011 Jan; 59(1):16-7. PubMed ID: 20970245
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of cytoreductive nephrectomy in the era of molecular targeted therapy.
    Polcari AJ; Gorbonos A; Milner JE; Flanigan RC
    Int J Urol; 2009 Mar; 16(3):227-33. PubMed ID: 19207114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific antitumour vaccine for renal cancer.
    Fishman M; Antonia S
    Lancet; 2004 Feb; 363(9409):583-4. PubMed ID: 14987879
    [No Abstract]   [Full Text] [Related]  

  • 11. Editorial comment on: Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
    Novara G
    Eur Urol; 2009 May; 55(5):1153-4. PubMed ID: 18930580
    [No Abstract]   [Full Text] [Related]  

  • 12. Editorial comment on: Observation should be considered as an alternative in management of renal masses in older and comorbid patients.
    Volpe A
    Eur Urol; 2009 Jun; 55(6):1428-9. PubMed ID: 19147272
    [No Abstract]   [Full Text] [Related]  

  • 13. Editorial comment on: Observation should be considered as an alternative in management of renal masses in older and comorbid patients.
    Remzi M
    Eur Urol; 2009 Jun; 55(6):1427-8. PubMed ID: 19147268
    [No Abstract]   [Full Text] [Related]  

  • 14. Editorial comment on: prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients.
    Ohlmann CH
    Eur Urol; 2010 Feb; 57(2):325-6. PubMed ID: 19136198
    [No Abstract]   [Full Text] [Related]  

  • 15. HLA class II haplotypes predict favorable outcomes for patients with metastatic RCC.
    Ellerhorst JA; Hildebrand WH; Cavett JW; Fernandez-Vina MA; Hodges S; Poindexter N; Fischer H; Grimm EA
    Urologe A; 2004 Sep; 43 Suppl 3():S137. PubMed ID: 15148575
    [No Abstract]   [Full Text] [Related]  

  • 16. Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma.
    Margulis V; McDonald M; Tamboli P; Swanson DA; Wood CG
    J Urol; 2009 May; 181(5):2044-51. PubMed ID: 19286220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editorial comment on: Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma.
    Mulders P
    Eur Urol; 2009 Jul; 56(1):132-3. PubMed ID: 18550266
    [No Abstract]   [Full Text] [Related]  

  • 18. Chronically administered immunotherapy with low-dose IL-2 and IFN-alpha in metastatic renal cell carcinoma: a feasible option for patients with a good prognostic profile.
    Vaglio A; Alberici F; Maggiore U; Buti S; Potenzoni D; Passalacqua R; Buzio C
    Oncology; 2009; 76(1):69-76. PubMed ID: 19047813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
    Ramsey S; Aitchison M
    J Urol; 2005 Dec; 174(6):2422-3. PubMed ID: 16280863
    [No Abstract]   [Full Text] [Related]  

  • 20. Editorial Comment on: Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas.
    Staehler M
    Eur Urol; 2007 Oct; 52(4):1155. PubMed ID: 17287072
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.